Rees; David Charles

Patent Applications and Registrations

Patent applications and USPTO patent grants for Rees; David Charles.The latest application filed is for "pyrazolyl quinoxaline kinase inhibitors".

Company Profile

9.18.25

Rees; David Charles - Cambridge GB

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Pyrazolyl Quinoxaline Kinase Inhibitors App 20220135544 - SAXTY; Gordon ; et al.	2022-05-05
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20220106287 - CHESSARI; Gianni ; et al.	2022-04-07
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity Grant 11,261,171 - Chessari , et al. March 1, 2	2022-03-01
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20210276984 - CHESSARI; Gianni ; et al.	2021-09-09
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity Grant 10,981,898 - Chessari , et al. April 20, 2	2021-04-20
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20200247789 - Kind Code	2020-08-06
Pyrazolyl Quinoxaline Kinase Inhibitors App 20200131153 - SAXTY; Gordon ; et al.	2020-04-30
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20200079761 - CHESSARI; Gianni ; et al.	2020-03-12
Isoindolinone inhibitors of the MDM2-p53 interaction having anticancer activity Grant 10,544,132 - Chessari , et al. Ja	2020-01-28
Isoindolinone inhibitors of the MDM2-P53 interaction having anticancer activity Grant 10,526,311 - Chessari , et al. J	2020-01-07
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20190055215 - CHESSARI; Gianni ; et al.	2019-02-21
Isoindolinone Inhibitors Of The Mdm2-p53 Interaction Having Anticancer Activity App 20190016708 - CHESSARI; Gianni ; et al.	2019-01-17
Pyrazolyl Quinoxaline Kinase Inhibitors App 20180127397 - SAXTY; Gordon ; et al.	2018-05-10
Pyrazolyl quinoxaline kinase inhibitors Grant 9,850,228 - Saxty , et al. December 26, 2	2017-12-26
Pyrazolyl Quinoxaline Kinase Inhibitors App 20160311800 - SAXTY; Gordon ; et al.	2016-10-27
Pyrazolyl quinoxaline kinase inhibitors Grant 9,464,071 - Saxty , et al. October 11, 2	2016-10-11
Bicyclic heterocycle compounds and their uses in therapy Grant 9,458,158 - Buck , et al. October 4, 2	2016-10-04
Bicyclic Heterocycle Compounds And Their Uses In Therapy App 20160083377 - BUCK; Ildiko Maria ; et al.	2016-03-24
Bicyclic heterocycle compounds and their uses in therapy Grant 9,155,743 - Buck , et al. October 13, 2	2015-10-13
Pyrazolyl Quinoxaline Kinase Inhibitors App 20150105368 - SAXTY; Gordon ; et al.	2015-04-16
Pyrazolyl quinoxaline kinase inhibitors Grant 8,895,601 - Saxty , et al. November 25, 2	2014-11-25
Substituted Benzylamine Compounds, Their Use In Medicine, And In Particular The Treatment Of Hepatitis C Virus (hcv) Infection App 20140288040 - Woodhead; Andrew James ; et al.	2014-09-25
Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases Grant 8,778,936 - Berdini , et al. July 15, 2	2014-07-15
Bicyclic Heterocycle Compounds And Their Uses In Therapy App 20140045831 - Buck; Ildiko Maria ; et al.	2014-02-13
Compositions comprising (S)-2-amino-1-(4-chlorophenyl)-1-[4-(1H-pyrazol-4-yl)-phenyl]-ethanol as modulator of protein kinases Grant 8,497,294 - Woodhead , et al. July 30, 2	2013-07-30
Pyrazolyl Quinazoline Kinase Inhibitors App 20130072457 - Saxty; Gordon ; et al.	2013-03-21
4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors Grant 8,293,767 - Wyatt , et al. October 23, 2	2012-10-23
Pyrazole Compounds That Modulate The Activity Of Cdk, Gsk And Aurora Kinases App 20120190673 - BERDINI; Valerio ; et al.	2012-07-26
Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases Grant 8,110,573 - Berdini , et al. February 7, 2	2012-02-07
4-(2,6-dichloro-benzoylamino)-1h-pyrazole-3-carboxylic Acid Piperidin-4-ylamide Acid Addition Salts As Kinase Inhibitors App 20110274616 - WYATT; Paul Graham ; et al.	2011-11-10
Compositions Comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol As Modulator Of Protein Kinases App 20110269808 - WOODHEAD; Steven John ; et al.	2011-11-03
4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors Grant 8,013,163 - Wyatt , et al. September 6, 2	2011-09-06
Compositions Comprising (s)-2-amino-1-(4-chlorophenyl)-1-[4-(1h-pyrazol-4-yl)-phenyl]-ethanol As Modulator Of Protein Kinases App 20100113551 - Woodhead; Steven John ; et al.	2010-05-06
4-(2, 6-Dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid (1-methanesulphonyl-piperidin-4-yl)-amide for the Treatment of Cancer App 20090318500 - Trewartha; Gary ; et al.	2009-12-24
4-(2,6-dichloro-benzoylamino)-1H-pyrazole-3-carboxylic acid piperidin-4-ylamide acid addition salts as kinase inhibitors App 20090012124 - Wyatt; Paul Graham ; et al.	2009-01-08
Pyrazole Compounds that Modulate the Activity of Cdk, Gsk and Aurora Kinases App 20080132495 - Berdini; Valerio ; et al.	2008-06-05
5-Morpholinylmethylthiophenyl Pharmaceutical Compounds As P38MAP Kinase Modulators App 20070208015 - Gill; Adrian Liam ; et al.	2007-09-06

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.